 
About the Program
Program Overview
The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 12th IAS Conference on HIV Science (IAS 2023). This program consists of two components: (1) CME Internet Symposium: IAS 2023 Expert Review: a CME Internet symposium that features an overview of key presentations and posters, selected by the expert faculty; and (2) Rapid-Fire Review of IAS 2023: a podcast that provides a brief, audio summary of the most essential data presented at the conference.
The CME Internet Symposium: IAS 2023 Expert Review will feature a panel of HIV experts reviewing and discussing key presentations on antiretroviral therapy presented at IAS 2023. The review and discussion will focus on HIV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations, therapies in development, epidemiology, and diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at www.viraled.com.
This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at IAS 2023 and it is not sanctioned by the organizers of IAS 2023.
Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
Learning Objectives
After completing these activities, participants should be better able to:
- Describe and apply in a clinical setting the most current HIV prevention and treatment approaches and paradigms
- Improve retention of patients on ARV therapy by addressing ARV side effects that can interfere with adherence to ARV regimens
- Support the rapid initiation of appropriate and effective antiretroviral therapy
- Characterize new antiretroviral agents in development and how they may be used in the treatment of people with HIV infection
Release Date: August 10, 2023
Expiration Date: August 10, 2024
Estimated time to complete the program: 30 minutes per module
Back to Top
Faculty
José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain
Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine
University Hospital
Bonn, Germany
Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois
Joint Accreditation Statement
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
|
Credit Designation
Module 1 (HIV Prevention, PrEP and Hot Topics):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Anitretroviral Treatment):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (Adverse Events and Co-morbidities):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (HIV and Co-infections):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|
Back to Top
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners,
and others in control of educational content to disclose all their
financial relationships with ineligible companies. All identified
conflicts of interest (COI) are thoroughly vetted and mitigated
according to PIM policy. PIM is committed to providing its learners with
high quality accredited continuing education activities and related
materials that promote improvements or quality in healthcare and not a
specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the content of this
CME activity:
Jose Arribas, MD
- Speakers Bureau/Honoraria for non-CME: ViiV, Gilead, MSD
- Consultant/Advisory Board: ViiV, GSK, Janssen, Gilead, MSD, Aelix, Serono, Lilly, Roche
Graeme Moyle, MD
- Consultant/Advisory Board: Gilead, Merck, Theratechnologies, ViiV
- Speakers Bureau/Honoraria for non-CME: Gilead, Merck, ViiV
- Grant/Research Support: NEAT Foundation, ViiV
Juergen Rockstron, MD
- Consultant/Advisory Board: Abivax, Boehringer, Gilead, Merck, ViiV
- Speakers Bureau/Honoraria for non-CME: Gilead, Merck, Janssen, ViiV
Renslow Sherer, MD
- Grant/Research Support: Gilead
Postgraduate Institute for Medicine and ViralEd, Inc. planners and managers have nothing to disclose.
Back to Top
Method of Participantion and Request for Credit
1) Go to http://www.cmeuniversity.com/
2) Login or Create a New Account (will take less than 1 minute)
a) If you receive a message when creating a new account that "the
email you entered is already in use", please click the Forgot my
Username or Password link to have your Username and Password sent to you
via email
b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3) Type in 18079 at the top of the page, "Find Post-Test/Evaluation by Course", and click enter
4) Click on the activity title when it appears
5) Choose the type of credit you desire
6) Complete the online Evaluation
7) Receive an immediate CE Certificate to download and/or print for your files
Back to Top
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications.
The opinions expressed in the educational activity are those of the
faculty and do not necessarily represent the views of the planners.
Please refer to the official prescribing information for each product
for discussion of approved indications, contraindications, and warnings.
Back to Top
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Back to Top
Computer System Requirements
This
program requires HTML 5 enabled web browsers such as; Microsoft Edge, Mozilla Firefox, Apple Safari or Google Chrome.
Back to Top
An Independent CME Activity Jointly Provided by Postgraduate Institute for Medicine and ViralEd, Inc.
This program has been supported by independent educational grants from Gilead Sciences, Inc. and Merck and Co., Inc.
|
